Menopause increases your risk of STIs due to how aging changes your body
Explanations for why these infections are so common in older adults include limited understanding of STIs in this age group, infrequent condom use and increased availability of medications for conditions that typically limit sexual activity in older adults, such as like Viagra and Cialis for erectile dysfunction and estrogen creams and tablets for vaginal dryness. Many older adults are reluctant to discuss their sexual history with their partners and health care providers, which contributes to misconceptions that they are monogamous or sexually inactive.
In my work as an infectious disease scientist, I examine the largely unexplored biological reasons for why postmenopausal women have increased susceptibility to STIs. My recently published research shows that menopause is associated with loss of the genital tract's protective barrier, an essential defense against the microbial pathogens that cause STIs.
Menopause: A natural part of aging
Menopause is the stage in a woman's life marked by no menstrual periods for 12 consecutive months. In the U.S., menopause begins on average between ages 45 and 55. It is estimated that by the year 2030, 1.2 billion women worldwide will be menopausal or postmenopausal.
Menopause results from a loss of estrogen production from the ovaries, which can diminish vaginal lubrication and vaginal tissue elasticity. This can cause a condition called genitourinary syndrome of menopause, or GSM, which involves symptoms such as vaginal dryness and irritation, painful sex and frequent urinary tract infections. Roughly half of postmenopausal women experience GSM.
In addition to these negative effects on vaginal health, research from my lab has found that menopause also compromises the structural integrity of the tissue lining the vagina. The surface of the vagina is composed of multiple layers of epithelial cells that are held together by numerous adhesion molecules, including the proteins desmoglein-1, or DSG1, and desmocollin-1, or DSC1. These proteins strengthen the vaginal lining and restrict pathogen access to deeper tissue, reducing the risk of infection.
To explore how menopause affects the vaginal lining, we compared the DSG1 and DSC1 levels in vaginal tissue from postmenopausal and premenopausal women. We found significantly lower DSG1 and DSC1 levels in postmenopausal women.
We then surgically removed the ovaries of mice to model the loss of ovarian estrogen production in postmenopausal women. We also detected significantly less DSG1 and DSC1 proteins in vaginal tissue from mice without ovaries compared with mice with intact ovaries.
Mice without ovaries also had greater susceptibility to infection with herpes simplex virus type 2, or HSV-2, and were less able to clear chlamydia infection from their lower genital tract. On the other hand, applying estrogen cream to mice without ovaries restored the integrity of their vaginal lining and fully protected these mice from HSV-2 infection.
Too important to ignore
Fully understanding the behavioral and biological risk factors that contribute to STI susceptibility can help clinicians and public health officials tackle the startling increases in STIs among older adults.
Together, our studies show there is a loss of integrity in the vaginal lining after menopause. While additional research is needed, findings from our lab suggest that estrogen-containing compounds used to relieve vaginal irritation and other symptoms of genitourinary syndrome of menopause can also reduce susceptibility to STIs among older adults.
In the meantime, health care providers can help reduce the risk of STIs among older adults by consistently counseling them about safe sex practices and offering routine STI screening.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Thomas L. Cherpes, The Ohio State University
Read more:
Millions of women are working during menopause, but US law isn't clear on employees' rights or employers' obligations
Iceland's recent volcanic eruptions driven by pooling magma are set to last centuries into the future
The sex of your cells matters when it comes to heart disease
Thomas L Cherpes receives funding from the National Institute on Aging and the National Institute of Child Health and Human Development
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Ultimate Pet Nutrition Launches Mobility Renew, A Breakthrough Joint Support Formula for Dogs
A Veterinarian-Formulated Soft Chew Joint Support Supplement Designed to Promote Flexibility, Soothe Stiffness, and Support Long-Term Mobility in Dogs LOS ANGELES, Aug. 5, 2025 /PRNewswire/ -- Ultimate Pet Nutrition® proudly announces the launch of Mobility Renew™, a veterinarian-developed soft chew supplement designed to support canine joint health, flexibility, and comfort. Crafted by renowned veterinarian Dr. Gary Richter, this premium formula combines clinically-studied ingredients to help dogs of all ages maintain active, comfortable lives.* "What looks like 'slowing down' is often discomfort," explains Dr. Richter. "I developed Mobility Renew to help improve their comfort and activity. A lot of research shows UCII collagen is more effective than glucosamine for joint support. Combined with hyaluronic acid, omega-3s, eggshell membrane, boswellia, and ashwagandha, I believe Mobility Renew is the most powerful joint supplement for dogs on the market."* Mobility Renew is a step above the conventional joint support supplements we have been using for the past twenty years. All this time, we have been largely relying on glucosamine and chondroitin for joints. While these compounds have their benefits, the UC-II collagen in Mobility Renew is much more effective, providing joint and cartilage support and comfort than the ingredients in yesterday's supplements. While the UC-II collagen alone can provide effective relief, the addition of joint support, antioxidants, and omega-3 fats helps promote a healthy joint environment in ways that the older supplements can't. The ingredients in Mobility Renew could be the future of supporting and maintaining optimal joint health in our pets.* What is Ultimate Pet Nutrition Mobility Renew?Ultimate Pet Nutrition Mobility Renew is an advanced hip and joint supplement formulated to support healthy joint function, reduce stiffness, and support cartilage and connective tissue in dogs. This daily soft chew is ideal for aging dogs, active breeds, or any pup experiencing occasional joint discomfort due to normal activity.* Featuring a synergistic blend of premium ingredients—including UC-II® Collagen, MSM, Eggshell Membrane, Salmon Oil, Hyaluronic Acid, and Boswellia—Mobility Renew™ offers comprehensive support for joint mobility and comfort. Each soft chew is designed to help ease joint stiffness, support cartilage development, and maintain healthy bone and joint function.* What sets Ultimate Pet Nutrition Mobility Renew apart from other dog joint supplements is its focus on clinically backed ingredients that can help improve mobility and flexibility. It's an ideal choice for pet parents seeking a natural, holistic approach to joint care. Plus, it's easy-to-administer soft chew format makes it simple to add to your dog's daily routine (as in, no need to hide in peanut butter to get them to eat it!).* Key Ingredients in Ultimate Pet Nutrition Mobility Renew UC-II® Collagen: A patented form of undenatured type II collagen that supports joint comfort, flexibility, and healthy joint function by targeting the root causes of stiffness. * Methylsulfonylmethane (MSM): A naturally occurring compound that supports joint health by promoting normal recovery after exercise. * Eggshell Membrane: Rich in naturally occurring compounds like collagen, elastin, and glycosaminoglycans, which are crucial for top-notch joint health.* Salmon Oil: Packed with omega-3 fatty acids, which have been shown to support healthy joint mobility and reduce occasional discomfort in dogs.* Hyaluronic Acid: A naturally occurring compound that acts as a lubricant for the joints, helping to support the joints during activity.* Boswellia: A natural herb that supports smooth, comfortable joint movement, especially after exercise or during periods of increased activity.* Ultimate Pet Nutrition Mobility Renew FAQ How do I use Ultimate Pet Nutrition Mobility Renew? To use Ultimate Pet Nutrition Mobility Renew, give the appropriate number of soft chews to your dog once per day based on the chart. Where can I purchase Ultimate Pet Nutrition Mobility Renew? Ultimate Pet Nutrition Mobility Renew can be purchased on for $49.95. About Ultimate Pet NutritionFounded by Dr. Gary Richter, Ultimate Pet Nutrition believes optimal nutrition is the key to a happy life. It's our mission to support your pet's health with premium quality food, treats, and supplements developed by Dr. Richter himself—because we understand your pet is like family, and they deserve only the best. In 2025, Dr. Richter teamed up with award-winning actor Rob Lowe, a dog dad himself and one of the most renowned actors and health advocates in the world, to spread the word about good nutrition and form a community that helps your pet live a happier, healthier life. Best-selling products include our popular freeze-dried raw dog food, Nutra Complete for Dog, and the popular freeze-dried raw treats, Nutra Bites. Ultimate Pet Nutrition products are also available on Amazon. Follow Ultimate Pet Nutrition on Instagram @ultimatepetnutrition and YouTube @ultimatepetnutrition. For retail opportunities, contact retail@ About Dr. Gary RichterDr. Gary Richter is a leader in integrating advanced Western medicine and Eastern holistic practices to provide comprehensive care for pets. As the founder of Ultimate Pet Nutrition, his unwavering dedication and passion for animals have earned him and his animal hospitals over 30 prestigious awards, including "Best Veterinarian" and "Best Alternative Medicine Provider." Dr. Richter is also the international best-selling author of The Ultimate Pet Health Guide and his latest books, Longevity for Cats and Longevity for Dogs, offering pet owners 'biohacking for pets" insight to help their pets live healthier, happier lives. To learn more, visit or follow him on Instagram @petvetexpert. *All pets are unique. Your results can and will vary. Press Contact:Laura Baumgartner - Asylum PRlbaumgartner@ View original content to download multimedia: SOURCE Ultimate Pet Nutrition Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board
SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced that Ray Deshaies, PhD, has joined its scientific advisory board. A biochemist and cell biologist, Dr. Deshaies most recently led global research for Amgen following a distinguished academic career at the California Institute of Technology. "I am deeply impressed with Iambic's team, its platform and application of AI and machine learning to address some of the most complex challenges in cancer and drug discovery," said Dr. Deshaies. "Iambic has differentiated itself by using its technology to uncover truly differentiated oncology candidates and rapidly advancing them into the clinic. I look forward to supporting the team's breakthrough science as they work to bring new therapies to patients." Prior to Amgen, Dr. Deshaies was a professor of biology at Caltech and an investigator at the Howard Hughes Medical Institute. His research focused on mechanisms and regulation of protein homeostasis in eukaryotic cells, with a particular focus on the ubiquitin-proteasome system and the degradation of proteins – work that provided the biochemical foundation for his lab's discovery of proteolysis-targeting chimeras (PROTACS) as a new class of candidate therapeutics. He also co-founded the biotechnology companies Proteolix and Cleave Biosciences and is a member of the American Academy of Arts and Sciences and the National Academy of Sciences. "We are thrilled to have Ray join our SAB and look forward to collaborating with him as we shape our pipeline of clinical programs and broaden the potential of our platform to unlock new targets for a range of critical disease areas," said Tom Miller, PhD, Iambic's co-founder and CEO. "Ray's achievements as a scientist, an innovator and a builder of world-class research organizations, make him an ideal partner as we continue to scale and define opportunities enabled by our AI-driven discovery engine." About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Lucid Diagnostics to Participate in Upcoming Investor Conferences
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences: 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference 1x1 Meetings: August 11-12, 2025 Location: Virtual Canaccord Genuity 45th Annual Growth Conference Fireside Chat: August 13, 2025, at 2:30 PM ET Location: Boston, MA The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data